Oncothermia: a new paradigm and promising method in cancer therapies
/in Hyperthermia, International PublicationsAutologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
/in Dendritic Cells, International Publications, Ovarian CancerA seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report
/in Hyperthermia, International Publications, Malignant Pleural Mesotheliomaα-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial
/in Dendritic Cells, Glioblastoma, International PublicationsGemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
/in Hyperthermia, International Publications, Pancreatic CancerThe immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses
/in Dendritic Cells, International Publications, Malignant MelanomaShort-term hyperthermia promotes the sensitivity of MCF-7 human breast cancer cells to paclitaxel
/in Breast Cancer, Hyperthermia, International PublicationsImmunotherapy with tumor vaccines for the treatment of malignant gliomas
/in Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer